Nifurtimox

Nifurtimox

SCHEMBL60839

CC1CS(=O)(=O)CCN1N=Cc1ccc([N+](=O)[O-])o1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 1.00
ALDH1A1 P00352 6/20 1.00
MAPT P10636 7/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
TP53 P04637 3/20 0.52
CYP1A2 P05177 3/20 0.52
HIF1A Q16665 2/20 0.52
CYP2D6 P10635 1/20 0.52
ALOX15 P16050 1/20 0.52
ATM Q13315 1/20 0.52
MITF O75030 3/20 0.51
TDP1 Q9NUW8 5/20 0.47
KDM4E B2RXH2 3/20 0.47
KMT2A Q03164 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
MEN1 O00255 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
NPC1 O15118 1/20 0.47
XBP1 P17861 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nifurtimox SCHEMBL1650162 1.00 LMNA (1.00) LMNAALDH1A1MAPTSMN1; SMN2TP53
Nifurtimox SCHEMBL9910611 1.00 LMNA (1.00) LMNAALDH1A1MAPTSMN1; SMN2TP53
Nifurtimox SCHEMBL60840 1.00 LMNA (1.00) LMNAALDH1A1MAPTSMN1; SMN2TP53
Nifurtimox SCHEMBL4727154 0.92 LMNA (0.85) LMNAALDH1A1MAPTSMN1; SMN2TP53
Nifurtimox SCHEMBL2326415 0.91 LMNA (0.83) LMNAALDH1A1MAPTSMN1; SMN2TP53
SCHEMBL23003602 0.88 LMNA (0.78) LMNAALDH1A1MAPTSMN1; SMN2TP53
SCHEMBL23003603 0.88 LMNA (0.78) LMNAALDH1A1MAPTSMN1; SMN2TP53
Nifurtimox SCHEMBL2326559 0.84 LMNA (0.70) LMNAALDH1A1MAPTSMN1; SMN2TP53
SCHEMBL12609083 0.80 LMNA (0.67) LMNAALDH1A1MAPTSMN1; SMN2TP53
SCHEMBL368127 0.78 LMNA (0.64) LMNAALDH1A1MAPTSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 4859 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4255391-B1 LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION METRIOPHARM AG (CH) 2026-05-06 EP claimed
US-20260091119-A1 ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA CELLIS AG (CH) 2026-04-02 US claimed
EP-4659760-A1 THERAPEUTIC IMMUNE INTERVENTION Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2025-12-10 EP claimed
EP-4637829-A1 ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF OVARIAN CANCER Cellis Sp. z o.o. ([Ltd.] (PL) 2025-10-29 EP claimed
EP-4587062-A1 ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA Cellis AG (CH) 2025-07-23 EP claimed
US-20250222066-A1 COMPOSITIONS AND METHODS OF TREATING, PREVENTING OR INHIBITING A FACULTATIVE ANAEROBE INFECTION UNIVERSITY OF UTAH RESEARCH FOUNDATION 2025-07-10 US claimed
US-12295957-B2 Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease IC-MedTech Corp. (US) 2025-05-13 US claimed
EP-4547023-A2 COMPOSITIONS AND METHODS OF TREATING, PREVENTING OR INHIBITING A FACULTATIVE ANAEROBE INFECTION University of Utah Research Foundation (US) 2025-05-07 EP claimed
WO-2025076059-A1 ROCAGLATE DERIVATIVES AND USES THEREOF TRUSTEES OF BOSTON UNIVERSITY (US) 2025-04-10 WO claimed
US-20250084059-A1 CRYSTALLINE FORMS OF C21H22Cl2N4O2 BIOMED VALLEY DISCOVERIES INC (US) 2025-03-13 US claimed
JP-2001500477-A 2001-01-16 JP claimed
EP-0925308-A2 COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN Micrologix Biotech, Inc. (CA) 1999-06-30 EP claimed
WO-1998007745-A2 COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN MICROLOGIX BIOTECH, INC. (CA) 1998-02-26 WO claimed
US-5646114-A Anti-protozoan methods XOMA CORPORATION (US) 1997-07-08 US claimed
EP-0364559-B1 SUBSTITUTED ADENINE DERIVATIVES USEFUL AS THERAPEUTIC AGENTS SCRIPPS RESEARCH INST (US) 1995-09-20 EP claimed
US-5332747-A Method for potentiating primary drugs in treating multidrug resistant parasitic disease cells CANCER BIOLOGICS OF AMERICA, INC. (US) 1994-07-26 US claimed
EP-0364559-A4 SUBSTITUTED ADENINE DERIVATIVES USEFUL AS THERAPEUTIC AGENTS 1991-01-09 EP claimed
EP-0364559-A1 SUBSTITUTED ADENINE DERIVATIVES USEFUL AS THERAPEUTIC AGENTS. SCRIPPS CLINIC RES (US) 1990-04-25 EP claimed
WO-1989008658-A1 SUBSTITUTED ADENINE DERIVATIVES USEFUL AS THERAPEUTIC AGENTS SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1989-09-21 WO claimed
EP-0305968-A2 Compositions against protozoal diseases YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) 1989-03-08 EP claimed